- Details
- Description
Mounjaro 2.5 mg KwikPen contains tirzepatide, a prescription medicine that acts on both GIP and GLP-1 receptors. It is administered as a once-weekly subcutaneous injection and is used to help improve blood-glucose control in adults with type 2 diabetes. Tirzepatide also reduces appetite and food intake, supporting weight loss and weight management when used alongside a healthy diet and increased physical activity where appropriate.
The 2.5 mg strength is generally used as the starting dose to help the body adjust to the medicine before the dose is increased if prescribed by a healthcare professional. Each KwikPen contains four weekly doses. Common side effects include nausea, diarrhea, vomiting, constipation, decreased appetite, and abdominal discomfort.
Mounjaro should be used only as prescribed by a healthcare professional, particularly when determining the appropriate dose and whether it is suitable for you.
The official product information confirms that each 2.5 mg KwikPen contains four 0.6 mL doses, with 2.5 mg tirzepatide per dose.
Important: For Manufacturer and Origin, don't put a single country unless you have checked the specific package/batch, because the approved manufacturers include facilities in Italy, Spain, France, and Ireland.
